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Background: Schizophrenia is a neurodevelopmental disorder with genetic and environmental factors contributing
to its pathogenesis, although the mechanism is unknown due to the difficulties in accessing diseased tissue during
human neurodevelopment. The aim of this study was to find neuronal differentiation genes disrupted in
schizophrenia and to evaluate those genes in post-mortem brain tissues from schizophrenia cases and controls.
Methods: We analyzed differentially expressed genes (DEG), copy number variation (CNV) and differential methylation
in human induced pluripotent stem cells (hiPSC) derived from fibroblasts from one control and one schizophrenia
patient and further differentiated into neuron (NPC). Expression of the DEG were analyzed with microarrays of
post-mortem brain tissue (frontal cortex) cohort of 29 schizophrenia cases and 30 controls. A Weighted Gene
Co-expression Network Analysis (WGCNA) using the DEG was used to detect clusters of co-expressed genes that
werenon-conserved between adult cases and controls brain samples.
Results: We identified methylation alterations potentially involved with neuronal differentiation in schizophrenia,
which displayed an over-representation of genes related to chromatin remodeling complex (adjP = 0.04). We found
228 DEG associated with neuronal differentiation. These genes were involved with metabolic processes, signal
transduction, nervous system development, regulation of neurogenesis and neuronal differentiation. Between
adult brain samples from cases and controls there were 233 DEG, with only four genes overlapping with the 228
DEG, probably because we compared single cell to tissue bulks and more importantly, the cells were at different
stages of development. The comparison of the co-expressed network of the 228 genes in adult brain samples
between cases and controls revealed a less conserved module enriched for genes associated with oxidative stress
and negative regulation of cell differentiation.
Conclusion: This study supports the relevance of using cellular approaches to dissect molecular aspects of
neurogenesis with impact in the schizophrenic brain. We showed that, although generated by different
approaches, both sets of DEG associated to schizophrenia were involved with neocortical development. The
results add to the hypothesis that critical metabolic changes may be occurring during early neurodevelopment
influencing faulty development of the brain and potentially contributing to further vulnerability to the illness.
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Schizophrenia is a severe and debilitating neuropsychi-
atric disorder with a worldwide prevalence of approxi-
mately 1 % and an estimated heritability of 80–85 % [1].
Multiple factors contribute to its pathogenesis, including
genetic and environmental factors [2–4], which are in-
volved in the disturbance of the neuronal network for-
mation and brain function [5].
Although the genetic component involvement is clear,
the precise molecular and cellular defects that precedes
illness onset and the sequence of mechanisms that initi-
ate or attenuate disease progression, particularly in neu-
rons, are still unknown. In addition to findings from
animal models [6–8], post-mortem human brain studies
in schizophrenia revealed significant alterations in genes
with high expression in multiple cortical and hippocam-
pal regions [9–13]. Data from prefrontal cortex obtained
post-mortem revealed 28 modules of co-expressed genes
associated to oxidative phosphorylation, energy produc-
tion and metabolism, post-translation modifications,
neurogenesis and neuronal differentiation. Additionally,
these modules showed a robust effect of age suggesting
that genes related to nervous system development process
and neuronal differentiation are deregulated in schizo-
phrenia [14]. A co-expression module analysis from pa-
tients with schizophrenia (SCZP) and controls of seven
studies showed that the top-modules of each study dis-
played a significant enrichment of neuronal markers as
well as genes related to the electron transport chain and
oxidative phosphorylation biological processes [15]. Even-
tually, these alterations, through the analyses of genes and
proteins, can be found in the peripheral blood suggesting
that they are potential molecular markers for diagnosis or
follow-up [16–19].
Promising approaches involve the study of tissue from
the olfactory system by nose biopsies [20] and the devel-
opment of human induced pluripotent cells (hiPSC)
techniques. The later demonstrated that functional pri-
marily glutamatergic neurons differentiated from hiPSC
were able to fire action potentials after eight weeks in
culture, showing the possibility of studying schizophre-
nia through this technique [21]. SCZP-hiPSC-derived
neurons display diminished neuronal connectivity with re-
duced neuritis and changes in Wnt and cAMP signaling
pathways when compared to controls [22]. Additionally,
RNA sequencing analysis of hiPSCs-derived neurons
highlighted the importance of long non-coding RNAs in
neurogenesis [23].
In a previous study, we showed that neural progenitor
cells (NPCs), derived from hiPSCs from skin fibroblasts
of a schizophrenic patient had a 2-fold increase in extra-
mitochondrial oxygen consumption compared to normal
controls, and correspondingly elevated levels of reactive
oxygen species (ROS), which was reduced to control levelsby addition of valproic acid [24]. Mitochondrial dysfunc-
tion was also associated with impaired differentiation of
neurons into both mature dopaminergic and glutamater-
gic phenotypes in schizophrenia-derived hiPSCs [25].
Although genes involved with ROS and other molecu-
lar mechanisms in hiPSC and NPC have been studied in
patients with schizophrenia [26], the ones specifically
disrupted in neuronal differentiation were not assessed
directly in adult brain samples. The aim of this study
was to disclose gene expression changes during neuronal
differentiation disrupted in schizophrenia and to expand
these findings to the brain tissue in adults. To achieve
that, genes identified as involved with neuronal differenti-
ation exclusively in schizophrenia were analyzed by co-
expression network in post-mortem brain samples derived
from adult patients and controls. Then, we identified the
biological processes associated with a less conserved mod-
ule between cases and controls brain samples.
Methods
Tissue collection
In short, biopsies of primary human fibroblasts from a
48 year-old woman with DSM-IV-TR schizophrenia defined
as treatment-resistant and under clozapine treatment
(SZCP) were collected in parallel with a control subject
(CON) that negative for any major lifetime DSM-IV-TR
diagnosis. Fibroblasts underwent primary culture procedures
to generate hiPSCs and were subsequently differentiated
into neurons (NPC). Details were previously described [24].
Total RNA was isolated from three plates of cell cul-
ture (with molecular confirmation for the cell type that
was being studied [24]) using Trizol (TRI Reagent,
Sigma-Aldrich, St Louis, MO, USA) according to the
manufacturer’s instructions. RNA quantity and integrity
were assessed by spectrophotometry (NanoDrop ND-
2000 UV–Vis Spectrophotometer, NanoDrop Technolo-
gies) and microfluidics-based electrophoresis (Agilent
2100 Bioanalyzer; Agilent Technologies, Santa Clara,
California), respectively, and obtained OD of ~2.0 and
RIN > 9. Genomic DNA was extracted using standard pro-
teinase K digestion followed by phenol/chloroform extrac-
tion. DNA quantity and integrity were assessed by
spectrophotometry (NanoDrop ND-2000 UV Spectropho-
tometer, NanoDrop Technologies) and agarosis gel 0.8 %.
The study protocol was approved by the ethics committee
of the Hospital de Clínicas de Porto Alegre, Porto Alegre
(RS) with all subjects providing written informed consent
co-signed by close relatives (Register 09-108). The study was
performed in accordance with the Declaration of Helsinki.
Comparative genomic hybridization based on microarray
(array-CGH)
We performed comparative genomic hybridization based on
microarrays (array-CGH) in a commercial whole-genome
Maschietto et al. BMC Medical Genomics  (2015) 8:23 Page 3 of 15180 K platform containing 180,000 oligonucleotide
probes (design 30864, Agilent Technologies, Palo Alto,
California) using as reference DNA a commercially
available human pool of healthy individuals (Promega).
Purification, cohybridization of labelled test and reference
DNA samples and washing were carried out according to
the manufacturer’s instructions. Scanned images were
processed using the Feature Extraction 10.7.3.1 software
(Agilent Technologies, Palo Alto, California).
Methylation experiments
Bisulfite-conversion of 500 ng of DNA was performed
according to the manufacturer’s recommendations (EZ
DNA Methylation Gold Kit, Zymo Research, Irvine,
California) for the Illumina Infinium Assay. The incuba-
tion profile was 16 cycles at 95 °C for 30 s, 50 °C
for 60 min and a final holding step at 4 °C for 10 min.
In total, 10 μl of bisulfite-converted DNA were used
for hybridization on Infinium HumanMethylation 450
BeadChip with 485,557 probes, following the Illumina
Infinium HD Methylation protocol (Illumina, Inc, San
Diego, California). All arrays passed Illumina standard
quality control metrics and were included in this study.
Microarray experiments
For mRNA expression, samples were prepared according
to the Agilent mRNA Microarray System protocol using
250 ng of total RNA for amplification and labelled using
the Agilent Low RNA Input Fluorescent Linear Amplifica-
tion Kit. Samples were hybridized in the Agilent Whole
Human Genome Microarray Kit, 4 × 44 K-G4112F in the
Agilent SureHyb chambers (Agilent Technologies, Palo
Alto, California) for 20 h at 55 °C, and the platforms were
washed with the manufacturer’s washing buffers. Controls
were used in all labelling reactions. Scanned images of the
arrays were processed using Feature Extraction 10.7.3.1
software (Agilent Technologies, Palo Alto, California) with
default parameters. Quality control of the probes (i.e. low
intensity, saturation, controls, etc.) selected 30,635 probes
corresponding to 22,186 transcripts for the analyses. From
those, 14,491 probes correspond to unique genes and
7695 were not associates with an ENTREZID. Four genes
had more than one ENTREZID with the same Official
Symbol and were excluded from the analyses.
Frontal cortical samples from a previous study were
used for further analyses, all presenting good quality
total and amplified RNA [27]. Postmortem brain tissue
was donated by The Stanley Medical Research Institute's
brain collection. Details about ethics regarding these
samples are available at the Neuropathology Consortium
(http://www.stanleyresearch.org). Comparing patients with
schizophrenia and controls, there were no significant dif-
ferences concerning age, brain weight or PMI, with only
pH showing a significant difference (p = 0.01). In short, 30controls subjects (CTS) and 29 patients with schizophrenia
(SZP) from the Stanley Foundation were hybridized in the
Agilent 4x44K human oligonucleotide microarray (Agilent
4112 F, Agilent Technologies, Palo Alto, California) follow-
ing manufacturer procedures. For analysis of replicate
spots, the average intensity after background correction
was calculated, followed by normalization using locally
weighted linear regression (LOWESS) with α = 0.2 within
slides using the R software version 2.11.1 (R Development
Core Team, 2010).
Data were deposited in NCBI Gene Expression Omni-
bus and are accessible through GEO Series accession
number GSE62191 and GSE62105.
Data analyses
DNA copy number variations (CNVs) were identified
with Nexus software 7.0 (Biodiscovery, Hawthorne, CA,
USA) using the FASST2 segmentation algorithm. To be
considered a CNV, the criteria were: a minimum of 3
consecutive affected probes (effective resolution of
~50 Kb for CNV calling), a significance threshold set at
5.0e−8, and threshold log2 ratio Cy3/Cy5 of 0.4 for gain
and −0.4 for loss. Data from sex chromosomes were ex-
cluded. Gene annotation was performed according to
the GRCh37/hg19using the University of California
Santa Cruz Genome Browser (http://genome.ucsc.edu/)
and the Database of Genomic Variants (DGV; May 2014
update).
Due to the low number of samples, we simplified the
methylation analyses. CpGs with β-values ≤0.2 were con-
sidered hypo-methylated and with β-values ≥0.8 were
considered hyper-methylated, which were used to con-
struct Venn-diagrams to compare the data in fibroblasts,
hiPSC and NPC.
For gene expression analyses, it was applied HT-self
[28]. Self–self experiments were performed by labelling
the hIPSC from SZCP with either Cy3 or Cy5 dyes and
hybridizing simultaneously on the same microarray slide
to determine the intensity dependent cut-offs. These
cut-offs were applied to the non-self–self experiment
that was performed in triplicate (SCZP × CON). To
identify differentially expressed genes, three criteria were
applied: a. each gene must be represented by at least two
probes; b. more than 50 % of the probes representing
that gene presented reliable signal; c. there was at least
80 % of signal agreement among probes. To avoid tech-
nical variability, only genes that reached the three cri-
teria in all replicates were selected.
To investigate if genes identified in this study could
have a role during foetal development of the prefrontal
cortex (dorsolateral prefrontal cortex, ventrolateral pre-
frontal cortex, anterior (rostral) cingulate (medial pre-
frontal) cortex), they were searched in the BrainSpan
database (Allan Brain Atlas) [29]. Genes with at least 1
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had an expression interquartile range >0.5 were consid-
ered for the analyses. Genes were assigned as foetal or
non-foetal according to the development stage of the
sample. It was considered differentially expressed those
genes with fold-change >2.
The Wilcoxon Rank Sum Test was applied using
TMEV software package [30] to identify differentially
expressed genes between 29 SZP and 30 CTS consider-
ing those with p < 0.01 as significantly differentially
expressed. As pH was significantly different in the brains
between cases and controls, we accessed the DEG which
expression was possibly being affected by pH. Hence, a
multiple regression analysis was applied for all expressed
genes in the microarray platform with a further compari-
son to 1000 permutated datasets. We observed that
the difference of pH in the brain affects around 20 %
of expressed genes (F, p < 0.05) of the whole array.
These genes were compared to the DEGs between SZP
and CTS.
The DEG sets found by both analyses were compared
to the findings of a published study that defined 17
modules comprised of co-expressed genes associated
with human cortical development. Briefly, to define
human brain development modules, RNA-sequencing
data from neocortical regions of the BrainSpan were
analyzed through co-expression networks using the R
package Weighted Gene Co-expression Network Analysis
(WGCNA) [31]. The identified modules were character-
ized using GO-Elite [32] for controlling the network-wide
false discovery rate. It was significant those pathways
that had >10 genes at Z-summary >2 and FDR < 0.01 [31].
To estimate the enrichment of the DEG sets among the
17 modules, the Modular Single-set Enrichment Test
(MSET) was applied with 10,000 permutations [33]. For
that, we calculated the probability of the DEG being sig-
nificantly represented in each module compared to 10,000
simulated sets of genes generated randomly from the
microarray background. For each DEG and module, the
p-value was calculated based on the number of simulated
randomized sets that contains equal or higher number of
genes belonging to the DEG in that module. Scatter
smooth plots were construct only for the modules that
had DEG over-representation (p-value ≤0.05) using the
module eigengene values identified by the study [31].
In this study, the preservation module function from
the WGCNA package in R were used to build unsigned
co-expression networks to characterize features of co-
expressed gene modules [34–36]. A pairwise correl-
ation matrix was computed for all gene pairs across all
samples, and an adjacency matrix was calculated by
raising the correlation matrix to the power of 7. This
threshold was chosen based on the scale-free topology
criterion, which is the smallest threshold that resultedin a scale-free R2 fit about 0.8, and used for all networks:
schizophrenia samples only and controls samples only.
For each pair of genes, a robust measure of network inter-
connectedness (topological overlap measure) was calcu-
lated based on the adjacency matrix. The topological
overlap based dissimilarity was then used as input for
average linkage hierarchical clustering. Finally, modules
were defined as branches of the resulting clustering tree.
To cut the branches, we used the hybrid dynamic tree-
cutting in order to have robustly defined modules. The
minimum module size was set to 20 genes with the deepS-
plit parameter set to 2. Each module was summarized by
the first principal component of the scaled (standardized)
module expression profiles (ME). Hub genes were assigned
as having high intramodular connectivity kME >0.75. To
discriminate changes in modules comparing SZP and CTS,
we performed a module Preservation analysis that identified
which modules were preserved in both datasets. For that,
a Z-summary was calculated to exclude the possibility of
randomness in preservation based on 1000 permutations,
and indicating if a module is strongly (Z-summary >10),
moderately (2 <Zsummary <10) or not preserved (Z-summary
<2). For visualization, the resulting modules were plotted using
Cytoscape [37].
For DEG, functional and disease enrichment analyses
were performed in WebGestalt [38] using the whole gen-
ome as background with a further analysis implemented
in DAVID (database http://david.abcc.ncifcrf.gov/). It was
considered those biological processes and pathways that
comprised more than 10 genes and FDR < 0.05.
Results
Characterization of molecular alterations potentially
interfering with gene expression
To refine the identification of genes regulated during
neuronal differentiation, copy number alterations were
characterized by array comparative genomic hybridization
(CGH). Most of the detected copy number variations
(CNVs) were present in all cell types (fibroblasts, hiPSCs
and NPCs), which precludes their characterization as an
acquired copy number alteration related to cell differenti-
ation. There was no CNVs found exclusively in NPC from
SCZP. Nevertheless, one large gain at 20q11.21 (1.2 MB)
was acquired by the hiPSC and maintained in the NPC
from the SCZP. The region contains 32 genes (Additional
file 1: Figure S1). There were no CNVs found exclusively
in NPC from SCZP.
To explore methylation alterations potentially involved
in neuronal differentiation in schizophrenia, we com-
pared NPCs, hiPSC and fibroblast from SCZP and CON,
selecting CpG sites differentially methylated exclusively
between hiPSCs and NPCs in SCZP and CON. A Venn-
diagram identified 51 (33 genes) and 5 (3 genes) CpG
sites as hypo- or hyperrmethylated, exclusively in SCZP,
Table 1 Signaling cellular pathways over-represented among
the 228 gene set
Pathway Statistical test Genes
MAPK signalling
pathway
C = 268;O = 13;E = 1.38;
R = 9.42; p = 1.47e09;
adjP = 1.50E-07
PDGFA, ATF4,
AKT1, CACNA1C,
DUSP6, CACNA1E,
CACNA1H, NLK,
CHUK, MAP3K5, NTF3,
FOS, PPM1V
Pathways in cancer C = 326;O = 13;E = 1.68;
R = 7.75; p = 1.80e08;
adjP = 7.74E-07
PDGFA, RARA, AKT1,
ITGA2, E2F3,
FH, SMO, CHUK,
FZD5, FOS, BID,
SPI1, HDAC2
Metabolic pathways C = 1130;O = 21;E = 5.82;
R = 3.61; p = 4.84e07;
adjP = 1.39E-05
IMPA1, TRDMT1,
HSD17B8, DPM1,
MGAT4B, CPOX, FH,
SPHK1, DCT,
GAL3ST1, PNMT,
PIK3C2A, ASNS, PC,
MTHFS, PPAP2B,
CDO1, HAAO,
ATP6V1C1, ALDH1A1, AGL
Criteria: at least 10 genes represented in the pathway and adjpvalue ≤0.05
(hypergeometric t test with p value adjusted by multiple test adjustment,
Benjamini and Hochberg [69])
C number of reference genes in the category number of genes in the gene set
and O in the observed category, E expected number in the category, R ratio of
enrichment, p p value from hypergeometric test, adjP value adjusted by the
multiple test adjustment (adjP)
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These genes were over-represented in specific locations
of the genome, 1p36, 10q22, 12q22 and 14q24 (adjusted
p-value, adjP < 0.05). We also found overrepresentation
of chromatin remodeling complex (adjP = 0.04), repre-
sented by DPF3, SMARCA2 and RERE. DPF3b interacts
with the histones H3 and H4 in an acetylation-sensitive
manner to regulate transcription [39]. SMARCA2 is a
member of the SWI/SNF family of proteins with helicase
and ATPase activities and thought to activate transcrip-
tion altering chromatin structure in specific sites [40].
RERE is a nuclear receptor co-repressor that binds to
the histone methyltransferase G9a orchestrating molecu-
lar events that lead to a stable methylation of histone
H3-lysine 9 [41].
Characterization of expression patterns in SCZP
Gene expression profiles from hiPSC (SCZP or CON) were
compared to the corresponding groups of differentiated
cells (i.e. NPCs) to identify differences during neuronal
differentiation. We considered that the analyses in CON-
derived cells identified DEG during neuronal differenti-
ation; there were 1658 up-regulated (range from 0.50
to 6.76) and 1698 down-regulated (ranging from −0.43
to −8.49) genes. Comparison of the SCZP-derived cells re-
vealed 752 up-regulated (range from 0.56 to 3.4) and 818
down-regulated (ranging from −0.54 to −4.97) genes. Sub-
sequently, to exclude genes associated with normal neur-
onal differentiation, up- and down-regulated genes in CON
and SCZP were compared to select those that were exclu-
sive for SCZP. The analysis revealed 228 genes (151
up- and 77 down-regulated) altered only during neuronal-
differentiation of the SCZP cells (Additional file 1: Table S2,
Figure S3), from which ten were described by studies
in schizophrenia. Most of them were related to nervous
system development and/or plasticity: NDEL1, ATF4,
AKT1, MDGA1, PDE4B, FEZ1, TF3, ADRBK2, CACNA1C,
ADRA2A (Additional file 1: Table S3). In agreement with
our data, 10 genes (ATF4, CACNA1C, CPE, CTSF, EPHA2,
GPR155, HOXB9, MYBL1, NLGN1, and PMAIP1) were
identified by an independent study that used a similar
design (hiPSC x NPC in schizophrenia cases) [26].
Using expression data from the prefrontal cortex of
Brain Span (Allen Brain Atlas), expression of the 228
gene set were compared between 16 foetal and 22 non-
foetal samples. Nine genes were not present in Allen
Atlas and 35 did not pass quality control (see material
and methods). From the remaining 184 genes, 73 (40 %)
were differentially expressed and therefore considered
important for brain development.
To explore the functional significance of the genes from
neurodevelopment associated with schizophrenia, we per-
formed unbiased Gene Ontology term enrichment and
pathway analyses of the 228 genes. The most noteworthybiological processes that were overrepresented were
metabolic processes, signal transduction, nervous system
development, regulation of neurogenesis and neuronal
differentiation. Among the cellular pathways, we found
over-representation of genes related to MAPK signaling
pathway, pathways in cancer and metabolic pathways
(Table 1). Finally, it was interesting to note that genes in-
volved with cancer, infectious, metabolic and brain disor-
ders (including stress, bipolar disorder and schizophrenia)
were overrepresented diseases (Table 2).
There were no overlap between the 228 DEG
and genes from the 20q11.1 gain observed in the schizo-
phrenic case. BACE1 was the only gene that was also
identified by the methylation analysis. This gene seems
to regulate proteins with important roles in developmental
process such as NGR1 [42], which overexpression results
in a schizophrenia-like behavior in a mouse model [43].
Comparison of deregulated genes from individual cells
and brain bulk samples
Comparison of gene expression profiling from 29 SZP
and 30 CTS (brain bulks) revealed 233 differentially
expressed transcripts (p < 0.01), of which 69 are unknown
transcripts. We observed 127 (75 genes) up- and 106 (89
genes) down-regulated transcripts, none of them surviving
the multiple correction. Furthermore, difference in pH of
Table 2 Diseases over-represented among the 228 gene set
Disease Statistical test Genes
Cancer or viral infections C = 951;O = 25;E = 4.90;R = 5.11;
p = 3.35e-11;adjP = 8.71e-10
RARA, WIF1, AKT1, LGALS3, RB1CC1, E2F3, FH, SPHK1,
DCT, FOS, BID, PDGFA, CD24, S100A7, EPHA2, PMAIP1,
SMO, RHOBTB2, CTNND1, SPI1, ETV1, ALDH1A1,
CEACAM1, HDAC2, MYB
Neoplasms C = 854;O = 22;E = 4.40;R = 5.00;
p = 7.90e-10;adjP = 1.03e-08
RARA, WIF1, AKT1, LGALS3, E2F3, FH, DCT, PDGFA, CD24,
S100A7, EPHA2, PMAIP1, FLT1, SMO, RHOBTB2, CTNND1,
SSTR1, SPI1, ETV1, ALDH1A1, CEACAM1, MYB
Drug interaction with drug C = 349;O = 13;E = 1.80;R = 7.24;
p = 4.00e-08;adjP = 3.47e-07
CEBPB, PPIB, KPNA4, RARA, AKT1, PMAIP1, ITGA2, ACTA1,
PACS1, STX4, FOS, BID, HDAC2
HIV C = 755;O = 18;E = 3.89;R = 4.63;
p = 9.30e-08;adjP = 6.04e-07
ADARB1, PPIB, KHDRBS1, MGAT4B, FURIN, PSMD7, PACS1,
FOS, EED, PIK3C2A, CEBPB, PSMB10, KPNA4, MANEA, DDX6,
ACTA1, GTF2H1, HLA-DOA
Bipolar disorder C = 344;O = 12;E = 1.77;R = 6.78;
p = 2.71e-07;adjP = 1.41e-06
IMPA1, ATF4, DUSP6, CACNA1C, MDGA1, CTSF, CIT, PDE4B,
FEZ1, NLGN1, NTF3, ADRBK2
Infection C = 516;O = 14;E = 2.66;R = 5.27;
p = 5.72e-07;adjP = 2.48e-06
MIF, PSMB10, PPIB, KPNA4, TBK1, MICB, FURIN, PACS1,
NKRF, IL13RA1, TICAM1, HLA-DOA, CEACAM1, PIK3C2A
Metabolic diseases C = 612;O = 15;E = 3.15;R = 4.76;
p = 8.02e-07;adjP = 2.61e-06
PC, PEX6, JAZF1, CST3, CPOX, TOP3A, APOA2, NEFH,
ADIPOR2, PYGL, LIPA, AGL, APOA1, BCL11A, ZMPSTE24
Leukemia C = 452;O = 13;E = 2.33;R = 5.59;
p = 7.65e-07;adjP = 2.61e-06
RCBTB1, RARA, ASNS, AKT1, HUWE1, PMAIP1, PRDM16,
DOK1, CASC5, BID, SPI1, BCL11A, MYB
Stress C = 464;O = 13;E = 2.39;R = 5.44;
p = 1.02e-06;adjP = 2.95e-06
ASNS, ATF4, MTF1, AKT1, PMAIP1, MICB, ACTA1, SGK1,
CHUK, MAP3K5, FOS, PRDX4, RPL11
Mental disorders C = 564;O = 14;E = 2.90;R = 4.82;
p = 1.62e-06;adjP = 3.79e-06
NDEL1, CACNA1C, MDGA1, ASPM, BACE1, CST3, PDE4B,
NEFH, FEZ1, NLGN1, NTF3, ADRBK2, CDK5R1, ADRA2A
Adhesion C = 647;O = 15;E = 3.33;R = 4.50;
p = 1.59e-06;adjP = 3.79e-06
TEK, CD24, AKT1, LGALS3, EPHA2, RB1CC1, MDGA1, ITGA2,
ACTA1, CADM3, PTPN12, NLGN1, CTNND1, CEACAM1, CLDN11
Neoplastic processes C = 411;O = 12;E = 2.12;R = 5.67;
p = 1.75e-06;adjP = 3.79e-06
WASF3, CD24, WIF1, AKT1, LGALS3, EPHA2, FLT1, SPHK1,
CTNND1, ETV1, ALDH1A1, CEACAM1
Death C = 343;O = 11;E = 1.77;R = 6.23;
p = 1.94e-06;adjP = 3.88e-06
RBM20, ATF4, AKT1, PMAIP1, SPHK1, HRK, BCLAF1, CHUK,
MAP3K5, BID, CDK5R1
Leukemia, myeloid C = 279;O = 10;E = 1.44;R = 6.96;
p = 2.14e-06;adjP = 3.97e-06
RARA, HUWE1, PMAIP1, PRDM16, DOK1, CUX1, HRK, BID, SPI1, MYB
Neoplasm C = 298;O = 10;E = 1.53;R = 6.52;
p = 3.84e-06;adjP = 6.24e-06
WASF3, CD24, AKT1, LGALS3, EPHA2, FURIN, CUX1, CTNND1,
ETV1, CEACAM1
Invasiveness
Nervous system diseases C = 694;O = 15;E = 3.57;R = 4.20;
p = 3.73e-06;adjP = 6.24e-06
ATXN7, USH1G, PC, PEX6, ASPM, BACE1, DUX4, CST3, SOX3,
NEFH, CACNA1H, FOXG1, GIGYF2, XK, CDK5R1
Breast C = 377;O = 11;E = 1.94;R = 5.67;
p = 4.79e-06;adjP = 7.33e-06
S100A7, CD24, AKT1, LGALS3, EPHA2, RB1CC1, FXYD3,
RHOBTB2, ALDH1A1, HDAC2, MYB
Neoplasms
Brain diseases C = 411;O = 11;E = 2.12;R = 5.20;
p = 1.08e-05;adjP = 1.56e-05
ATXN7, PC, PEX6, BACE1, CST3, NEFH, AQP1, CACNA1H,
FOXG1, GIGYF2, CDK5R1
Schizophrenia C = 360;O = 10;E = 1.85;R = 5.40;
p = 1.98e-05;adjP = 2.57e-05
NDEL1, ATF4, AKT1, CACNA1C, MDGA1, PDE4B, FEZ1, NTF3,
ADRBK2, ADRA2A
Central nervous system diseases C = 438;O = 11;E = 2.25;R = 4.88;
p = 1.94e-05;adjP = 2.57e-05
ATXN7, PC, PEX6, BACE1, CST3, NEFH, CACNA1H, FOXG1,
GIGYF2, XK, CDK5R1
Virus diseases C = 488;O = 11;E = 2.51;R = 4.38;
p = 5.16e-05;adjP = 6.39e-05
CXCL5, PSMB10, KPNA4, TBK1, MICB, ACTA1, PSMD7, TICAM1,
HLA-DOA, FOS, PIK3C2A
Carcinoma C = 522;O = 11;E = 2.69;R = 4.09;
p = 9.37e-05;adjP = 0.0001
S100A7, CD24, WIF1, AKT1, LGALS3, EPHA2, SMO, FH,
CTNND1, ALDH1A1, CEACAM1
Pathologic processes C = 561;O = 10;E = 2.89;R = 3.46;
p = 0.0007;adjP = 0.0008
MIF, CXCL5, CD24, HTRA1, PRDM16, JAZF1, ITGA2, FLT1,
ZMIZ1, LOXL1
Maschietto et al. BMC Medical Genomics  (2015) 8:23 Page 6 of 15
Table 2 Diseases over-represented among the 228 gene set (Continued)
Syndrome C = 654;O = 10;E = 3.37;R = 2.97;
p = 0.0022;adjP = 0.0024
WASF3, USH1G, PEX6, WASL, TOP3A, FH, FOXG1, LOXL1,
XK, ZMPSTE24
Genetic C = 808;O = 10;E = 4.16;R = 2.40;
p = 0.0095;adjP = 0.0099
MIF, CACNA1C, HTRA1, JAZF1, ITGA2, PDE4B, ZMIZ1,
LOXL1, GIGYF2, ADRA2A
Predisposition to
Disease
Criteria: at least 10 genes represented in the pathway and adjpvalue ≤0.05 (hyper-geometric t test with p value adjusted by multiple test adjustment, Benjamini
and Hochberg [69])
C number of reference genes in the category number of genes in the gene set and O in the observed category, E expected number in the category, R ratio of
enrichment, p p value from hypergeometric test,. adjP value adjusted by the multiple test adjustment (adjP)
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the differentially expressed transcripts (Additional file 1:
Table S4).
To gain further information of the 228 and 233 DEG
sets, they were mapped to the gene co-expression mod-
ules from human cortical development [31]. The enrich-
ment analysis point out that each set of DEGs had over-
represented genes but in different modules (M). While
the set of 228 genes was enriched in M8, the set of 233
genes was enriched in M1, M5 and M15 (Additional file
1: Table S5). M8 and M15 were representative of genes
preferentially expressed in “early” and “late” foetal period
in human brain development, respectively (Additional
file 1: Figure S4). This finding suggests that both datasets
are related to neurodevelopment genes, but to different
stages of the brain development.
To expand our findings from a cellular model of
neuronal differentiation to postmortem samples from
human brains, the 228 gene set, found exclusively in
SCZP were compared to the 233 differentially expressed
genes from adult brain samples. There were 194 genes
out of the 228 represented in both platforms, from
which four genes were common to both analyses: AQP1,
DUSP6, FOS and TRIM24. Only DUSP6 and FOS have
been described in schizophrenia [44, 45]. None of the
them were affected by the pH difference.
Further, to identify functional modules in patients and
controls, a co-expression analyses of the 194 genes was
performed in WGCNA. Modules for CTS and SZP were
generated using the Scale-free Topology Criterion with
power 7. Four modules were identified plus the grey
module (Fig. 1a). Genes and biological processes over-
represented in each module are displayed in Tables 3
and 4, respectively. The best preserved module in SZP
compared to CTS is the blue (blue, Z-summary >10,
Fig. 1B) which had an overrepresentation of genes re-
lated to cell cycle.
Although showing a moderate Z-summary, using the
median rank value based on the observed values (less
dependent on modules sizes), the turquoise module was
only marginally preserved (2 < Z-summary <10). Since
this module includes negative regulation of cell differen-
tiation and response to oxidative stress processes,identified deregulated in these same cells [24], Pearson
correlation of paired genes were plotted (Fig. 1C). We
can observe a change of correlations in SZP compared
to CTS (change of color and thickness of lines linking
two genes). Whilst co-expressed genes related to regula-
tion of cell cycle processes, protein phosphatase binding
and nonsense mRNA decay were extremely conserved
between SZP and CTS, genes related to response to
negative regulation of cell differentiation and oxidative
stress were not.
Next, we defined the hub genes of the modules as those
genes with high module connectivity (kME >0.75). This
resulted in 13 hubs (CAPRIN1, CLIP4, CTNND1, GRB10,
KHDRBS1, KPNA4, LYPD6, NRL, PSTK, RANBP2, RINT1,
WASF3 and ZNF99) in the highly preserved blue module
of CTS, all conserved in SZP (which gained additional
four hubs: ZMIZ1, ORMDL1, EIF5 and FAM133B). It is
interesting to note that in the yellow and brown modules,
the number of hubs in SZP is smaller than in CTS, but all
hubs identified in SZP were conserved from CTS, with
only one exception in the yellow module (AKT) and one
in the brown module (ZMPSTE24).
The marginally preserved turquoise module had 13
and 16 hub genes in CTS and SZP, respectively, with
an overlap of only eight hubs, from which three were
previously associated with schizophrenia: ADARB1 [46],
PNOC [47] and XK [48]. Furthermore, three out of seven
hubs found only in SZP were previously associated with
schizophrenia. ADRA2A is required for normal pre-
synaptic control of transmitter release in noradrenergic
neurons and has polymorphisms associated to the in-
creased risk of developing the disease [49]. CIT is a
serine/threonine protein kinase involved in central ner-
vous system development and cancer cells proliferation.
Polymorphisms in CIT also seems to have an impact
in the risk of developing schizophrenia [50]. LIN7A en-
codes a protein involved with the synaptic function and
neuron migration in cerebral cortex development [51]
and was associated to autism and attention deficit hyper-
activity disorder [52, 53]. Even though the other four
hubs (ARMC8, BCL11A, CDO1 and FOXG1) have not
been linked to schizophrenia, they are candidates for
further studies.
Fig. 1 Module preservation analysis. a Dendrograms produced by average hierarchical clustering using topological overlapping matrix
dissimilarity. Colours represent different modules. Upper panel shows modules in control subjects (CTS; blue, brown, yellow and turquoise)
compared to patients with schizophrenia (SZP). Lower panel shows modules in patients with schizophrenia (blue, brown and turquoise) compared
to modules in control subjects. b Left panel shows the median preservation rank (y-axis) in relation to module size (x-axis). Each circle represents a
module labelled in different colours (blue, turquoise, yellow and brown). Right panel shows the Zsummary (y-axis) in function of module size.
Dashed lines represent thresholds 2 and 10: ≥10: high preservation; 2 < Zsummary <10: moderate preservation; <2: low preservation. The panels
show that the blue module is more preserved in control and patients whilst the turquoise module is less preserved. c Connectivity patterns
(correlation network adjacencies) between genes from the turquoise module in controls (control) and patients (schizophrenia) showing a large loss
of connectivity among genes in patient’s module compared to control modules. Line thickness represents the connectivity pattern and line colour
reflects the absolute correlation: −1 (negative) to 1 (positive). This module is enriched in genes related to response to negative regulation of cell
differentiation and oxidative stress
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Table 3 Genes preserved in the modules of the respective samples
Module Genes
Blue AGL, ANAPC4, APOA1, ARMCX6,
ASPM, ATF4, BCLAF1, BID, CAPRIN1,
CENPJ, CLIP4, CPOX, CTNND1,
EDNRA, EIF3A, EIF5, EPHA2, FAM133B,
GMFB, GRB10, HLA-DOA, HSD17B8,
ING5, KHDRBS1, KPNA4,
LYPD6, LZTS1, METTL16, MOCS3, NLGN1,
NPR1, NRL, ORMDL1, PC, PSMB10, PSTK,
RANBP2, RINT1, SMG5, SPHK1, STX4,
USH1G, WASF3, WDR44, ZMIZ1,
ZNF426, ZNF99
Brown CACNA1C, CACNA1E, CCAR1, CEACAM1,
EED, EIF3J, FURIN, GJD3, HDAC2, HUWE1,
ING3, LGALS3,
LOC389634, MANEA, METAP2, MRPL19,
MTHFS, NEK6, NOC3L, NUP107, PDK2,
PMAIP1, PPM1B,
PRDX4, PTPN12, PYGL, RCBTB1, SCAF8,
SNTB1, TEK, TRIM24, USP1, ZMPSTE24
Grey CCDC149, CEBPB, DDX6, FLT1, GIGYF2,
KCNK15, KDELC2, RARA, RARS, SLC38A4,
TBK1, TMEM208, TRDMT1, ZNF614
Turquoise ACTA1, ADARB1, ADIPOR2, ADRA2A,
ALDH1A1, AQP1, ARMC8, ATP6V1C1,
BCL11A, CDO1, CHUK, CIT,
CLDN11, COL9A3, CST3, CTDSP1, CUX1,
CXCL5, DCLRE1A, DHX36, DOK1, DPM1,
DYNC2H1, E2F3,
EPC1, ETV1, FAM204A, FGD4, FH, FOS,
FOXG1, FOXN2, FXYD3, FZD5, GAL3ST1,
GFOD1, GTF2H1,
HEY2, HRK, HS6ST2, IL13RA1, IMPA1,
ITGA2, LIN7A, LIPA, LOXL1, LRRC49,
MAP3K5, MTF1, MYB,
NDEL1, NKRF, NLK, PEX6, PFN2, PLOD2,
PNOC, PNPT1, PPAP2B, PPIB, PPIP5K2,
PRDM16, RAD54B,
RB1CC1, SARNP, SGK1, SMO, SOX3, SRSF1,
SSTR1, WASL, WIF1, XK, ZNF273
Yellow ADRBK2, AKT1, ASIC2, ASNS, CACNA1H,
CADM3, CD24, CDK5R1, DUSP6, FBRS,
GPR155, HNRNPH1, MDGA1, MGAT4B,
MICB, MYBL1, PACS1, PDE4B, PDGFA,
PNMT, PPP1R13B, RANGRF, RHOBTB2,
RIPK4, SPRY4, TICAM1
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In the present study, we characterized molecular alter-
ations during the differentiation of hiPSCs to NPCs from
a patient with schizophrenia and health control and ana-
lyzed the identified genes in the adult brain tissue from
schizophrenia cases and controls to study biological
processes that could be disrupted in the disease. As we
faced the limitation of a direct comparison due to the
different nature of samples (single cell type–neuron–
versus all cells types–frontal cortex), we decided to makethe analyses using gene co-expression network comple-
mented with the exploration of biological processes.
This allowed us to explore genes expressed during neur-
onal differentiation and important for the development
of schizophrenia in the context of adult brain bulk.
It is known that cultured cells are more likely to have
genomic instability, genetic and epigenetic mutations
[54, 55]. However, we only found one alteration by
aCGH, a 1.2 MB gain in SCZP-hiPSC that was main-
tained in the NPC, suggesting that genes in this region
may not be essential for the initial stages of neuron dif-
ferentiation. Even though none of the 228 DEG was lo-
cated in this region, it might contains regulatory variants
with some role in the disease, although they were not
explored in this study. The differentially methylated sites
found during neuronal differentiation were preferentially
associated with chromatin remodeling complex bio-
logical function, an interesting finding considering the
previous study where the oxidative stress present in
SCZP-NPC was reverted to NPC control levels after
treatment of valproic acid (VPA), a histone deacetylase
(HDAC) inhibitor [24].
Despite the fact that total RNA was extracted from three
independent cell cultures (hiPSC and NPC), we are aware
of the limitation of comparing one case with one control,
which is the reason why we used the HT-self model for
gene expression analyses. This consists in a mathematical
model developed to analyze low numbers of samples [28].
Moreover, we used very stringent criteria in all analyses to
identify the DEG and overrepresented ontologies (e.g. to
be considered overrepresented, each class should contain
more than 10 genes and a significant p-value after correc-
tion for multiple comparisons). Yet, data interpretations
present certain limitations.
Concerning the genes involved with neuronal differen-
tiation (hiPSC versus NPC), our comparisons revealed
that cells derived from health control displayed twice
more DEG than cells derived from the patient with
schizophrenia. This finding may be involved with the
disruption of cell differentiation that has been described
by other studies in schizophrenia. The 228 gene set asso-
ciated with neuronal differentiation in a patient with
schizophrenia had over-representation of pathways clas-
sically related to cancer, such as MAPK and metabolic
cellular pathways. Whilst new categories may appear
with the advance of research in the field, many aspects
of normal development and cancer have association
to neuronal disorders [56]. There are no implications
for tumorigenesis risk, although patients with schizo-
phrenia are at a reduced risk of developing cancer [57].
In our previous study with these cells, we demonstrated that
SZCP-NPC had altered metabolism compared to CON-
NPC [24]. Likewise, the 228 set had over-representation of
genes related to energy, lipid and carbohydrate metabolism,
Table 4 Biological processes overrepresented in the modules
Module GO ID Ontology name Ontology definition
Blue GO:0010564 regulation of cell cycle process Any process that modulates a cellular process
that is involved in the progression of biochemical
and morphological phases and events that occur
in a cell during successive cell replication or nuclear
replication events.
GO:0000086 G2/M transition of mitotic cell cycle Progression from G2 phase to M phase of the
mitotic cell cycle. The molecular event responsible
for this transition is the activation of the major cell
cycle cyclin-dependent kinase (e.g. Cdc2 in S. pombe,
CDC28 in S. cerevisiae, Cdk1 in human).
GO:0051325 interphase A cell cycle process comprising the steps by which a
cell progresses through interphase, the stage of cell
cycle between successive rounds of chromosome
segregation. Canonically, interphase is the stage of
the cell cycle during which the biochemical and
physiologic functions of the cell are performed and
replication of chromatin occurs.
GO:0051329 interphase of mitotic cell cycle Interphase occurring as part of the mitotic cell cycle.
Canonically, interphase is the stage of the cell cycle
during which the biochemical and physiologic functions
of the cell are performed and replication of chromatin
occurs. A mitotic cell cycle is one which canonically
comprises four successive phases called G1, S, G2, and
M and includes replication of the genome and the
subsequent segregation of chromosomes into daughter cells.
GO:0007346 regulation of mitotic cell cycle Any process that modulates the rate or extent of progress
through the mitotic cell cycle.
GO:0000278 mitotic cell cycle Progression through the phases of the mitotic cell cycle,
the most common eukaryotic cell cycle, which canonically
comprises four successive phases called G1, S, G2, and M
and includes replication of the genome and the subsequent
segregation of chromosomes into daughter cells. In some
variant cell cycles nuclear replication or nuclear division
may not be followed by cell division, or G1 and G2 phases
may be absent.
GO:0045184 establishment of protein localization The directed movement of a protein to a specific location.
GO:0016482 cytoplasmic transport The directed movement of substances (such as macromolecules,
small molecules, ions) into, out of, or within the cytoplasm of a cell.
Brown GO:0006508 proteolysis The hydrolysis of proteins into smaller polypeptides and/or
amino acids by cleavage of their peptide bonds.
GO:0030163 protein catabolic process The chemical reactions and pathways resulting in the breakdown
of a protein by the destruction of the native, active configuration,
with or without the hydrolysis of peptide bonds.
GO:0044257 cellular protein catabolic process The chemical reactions and pathways resulting in the breakdown
of a protein by individual cells.
GO:0044267 cellular protein metabolic process The chemical reactions and pathways involving a specific protein,
rather than of proteins in general, occurring at the level of an
individual cell. Includes cellular protein modification.
GO:0042593 glucose homeostasis Any process involved in the maintenance of an internal steady
state of glucose within an organism or cell.
GO:0019538 protein metabolic process The chemical reactions and pathways involving a specific protein,
rather than of proteins in general. Includes protein modification.
GO:0006325 chromatin organization Any process that results in the specification, formation or
maintenance of the physical structure of eukaryotic chromatin.
GO:0016568 chromatin modification The alteration of DNA, protein, or sometimes RNA, in chromatin,
which may result in changing the chromatin structure.
Grey GO:0017148 negative regulation of translation Any process that stops, prevents, or reduces the frequency, rate
or extent of the chemical reactions and pathways resulting in
the formation of proteins by the translation of mRNA.
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Table 4 Biological processes overrepresented in the modules (Continued)
GO:0035264 multicellular organism growth The increase in size or mass of an entire multicellular organism,
as opposed to cell growth.
GO:0042035 regulation of cytokine biosynthetic process Any process that modulates the frequency, rate or extent of the
chemical reactions and pathways resulting in the formation
of cytokines.
GO:0042089 cytokine biosynthetic process The chemical reactions and pathways resulting in the formation
of cytokines, any of a group of proteins that function to control
the survival, growth and differentiation of tissues and cells, and
which have autocrine and paracrine activity.
GO:0042107 cytokine metabolic process The chemical reactions and pathways involving cytokines, any
of a group of proteins or glycoproteins that function to control
the survival, growth and differentiation of tissues and cells, and
which have autocrine and paracrine activity.
GO:0006399 tRNA metabolic process The chemical reactions and pathways involving tRNA, transfer
RNA, a class of relatively small RNA molecules responsible for
mediating the insertion of amino acids into the sequence of
nascent polypeptide chains during protein synthesis. Transfer
RNA is characterized by the presence of many unusual minor
bases, the function of which has not been completely established.
GO:0014065 phosphatidylinositol 3-kinase cascade A series of reactions, mediated by the intracellular
phosphatidylinositol 3-kinase (PI3K). PI3K cascades lie
downstream of many cell surface receptor linked signaling
pathways and regulate numerous cellular functions.
GO:0014066 regulation of phosphatidylinositol
3-kinase cascade
Any process that modulates the frequency, rate or extent of
signal transduction mediated by the phosphatidylinositol
3-kinase cascade.
GO:0014068 positive regulation of phosphatidylinositol
3-kinase cascade
Any process that activates or increases the frequency, rate
or extent of signal transduction mediated by the
phosphatidylinositol 3-kinase cascade.
Turquoise GO:0006366 transcription from RNA polymerase
II promoter
The synthesis of RNA from a DNA template by RNA polymerase
II, originating at an RNA polymerase II promoter. Includes
transcription of messenger RNA (mRNA) and certain small
nuclear RNAs (snRNAs).
GO:0000003 reproduction The production by an organism of new individuals that contain
some portion of their genetic material inherited from that organism.
GO:0045596 negative regulation of cell differentiation Any process that stops, prevents, or reduces the frequency, rate
or extent of cell differentiation.
GO:0006357 regulation of transcription from RNA
polymerase II promoter
Any process that modulates the frequency, rate or extent of
transcription from an RNA polymerase II promoter.
GO:0022414 reproductive process A biological process that directly contributes to the process of
producing new individuals by one or two organisms. The new
individuals inherit some proportion of their genetic material
from the parent or parents.
GO:0006979 response to oxidative stress Any process that results in a change in state or activity of a cell
or an organism (in terms of movement, secretion, enzyme
production, gene expression, etc.) as a result of oxidative stress,
a state often resulting from exposure to high levels of reactive
oxygen species, e.g. superoxide anions, hydrogen peroxide
(H2O2), and hydroxyl radicals.
GO:0032990 cell part morphogenesis The process in which the anatomical structures of a cell part are
generated and organized.
GO:0006351 transcription, DNA dependent The cellular synthesis of RNA on a template of DNA.
Yellow GO:0045859 regulation of protein kinase activity Any process that modulates the frequency, rate or extent of
protein kinase activity.
GO:0043549 regulation of kinase activity Any process that modulates the frequency, rate or extent of
kinase activity, the catalysis of the transfer of a phosphate
group, usually from ATP, to a substrate molecule.
GO:0043409 negative regulation of MAPK cascade Any process that stops, prevents, or reduces the frequency, rate
or extent of signal transduction mediated by the MAPKKK cascade.
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Table 4 Biological processes overrepresented in the modules (Continued)
GO:0002764 immune response-regulating signaling pathway The cascade of processes by which a signal interacts with a
receptor, causing a change in the level or activity of a second
messenger or other downstream target, and ultimately leading
to the activation, perpetuation, or inhibition of an immune response.
GO:0050865 regulation of cell activation Any process that modulates the frequency, rate or extent of cell
activation, the change in the morphology or behavior of a cell
resulting from exposure to an activating factor such as a cellular
or soluble ligand.
GO:0002682 regulation of immune system process Any process that modulates the frequency, rate, or extent of an
immune system process.
GO:0002684 positive regulation of immune system process Any process that activates or increases the frequency, rate, or
extent of an immune system process.
GO:0010741 negative regulation of intracellular protein
kinase cascade
Any process that decreases the rate, frequency or extent of a
series of reactions, mediated by protein kinases, which occurs as
a result of a single trigger reaction or compound.
GO:0001932 regulation of protein phosphorylation Any process that modulates the frequency, rate or extent of
addition of phosphate groups into an amino acid in a protein.
GO:0010627 regulation of intracellular protein kinase cascade Any process that modulates the rate, frequency or extent of a
series of reactions, mediated by protein kinases, which occurs as
a result of a single trigger reaction or compound.
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evidence for the implication of tumor-suppressor and on-
cogenes to neurodevelopment and associated disorders.
Additionally, gene expression profiling from post-
mortem brain tissue of patients with schizophrenia and
controls were studied. To begin with, although there were
no significant differences in age or PMI, the pH was
slightly lower in the brain of patients with schizophrenia,
a characteristic that has been described although not con-
sidered for the analyses [15]. The pH may have an effect
on the expression of some genes or these genes might be
regulating the pH change. We found that 78 out of 233
DEG identified by the comparison between brain bulks
from patients with schizophrenia and health controls had
their expression also associated to differences in pH, an
issue that needs to be deeper investigated.
Likewise, to explore the relationship between genes in-
volved in neuronal differentiation and fully differentiated
brains in patients with schizophrenia, we have to consider
some additional known limitations: (1) Use of medication,
hypoxia and/or injury are known confounding factors in
the samples derived from the patients; (2) Comparison
between data generated by single cell types (hiPSC and
NPC) with data representing a mixed cell population
at the end stage of the disease (a “whole brain tissue”
that includes the glia, immunological and vascular cells);
3) Different methods were used to identify differentially
expressed genes; (4) Genes from neurodevelopment are
not being expressed or are being expressed at very low
levels once the brain has ended its maturation. Support-
ing this later hypothesis, the comparison of the 228 and
233 DEG with modules derived from developing brains
[31], showed that even though both sets have genesassociated with neurodevelopment, they are representa-
tive of different stages. Thus, the overlap of only four
genes was not a surprise.
Consequently, we decided to study the 228 gene set
using co-expression modules in the expression data from
the cohort of post-mortem cases of schizophrenia and
controls identifying a well preserved module (blue) and,
although not completely, a less conserved module (tur-
quoise). The blue module was associated with regulation
of cell cycle progress, protein phosphatase binding and
nonsense mRNA decay. Genes from this module have
function related to genome maintenance, RNA integrity,
cell proliferation and/or differentiation, such as ANPC4,
SPHK1 and SPP [60–62].
The turquoise module displays a set of genes involved
in negative regulation of cell differentiation and oxidative
stress response, more specifically reactive oxygen species
(ROS) production, mitochondria function and neuron
differentiation, which are closely related to the functional
study of these cells that exhibited deregulation of mito-
chondria function in SZCP-NPC [24]. Among the genes
represented in the module, three genes have a described
function associated with ROS generation. ASK1 is a mem-
ber of the mitogen-activated protein kinase family acti-
vated by cellular stress, activating c-jun N-terminal kinase
(JNK) and p38 in response to oxidative stress, endoplas-
mic reticulum stress, infection and calcium influx [63].
PNPT1 is predominantly localized in the mitochondrial
inter-membrane space and is implicated in RNA targeting
to human mitochondria, small noncoding nuclear RNAs
(5S rRNA, MRP RNA, some tRNAs, and miRNAs) [64].
cAMP-induced cFos is a transcriptional repressor of
CD44 that triggers ROS generation [65]. Additionally,
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ciated to neuronal plasticity and different cancers, most of
them associated to cell proliferation. Likewise, some of the
hub genes have already been associated to neurodevelop-
ment disorders.
Mitochondria activity and energy metabolism undergo
dramatic remodeling during embryonic development.
Early embryos are initially dependent upon oxidative
metabolism due to inheritance of maternal mitochondria
which are subsequently segregated among daughter cells.
A predominantly glycolytic metabolism provides suffi-
cient energy to support stem cells in basal state, but a
robust metabolic network is required to adequate the in-
creasingly energetic demands [66]. The established initial
mechanism support flux through the tricarboxylic acid
cycle and electron transport chain whilst mitochondrial
oxidization of pyruvate and glutamine to CO2 is opti-
mized to extract maximal energetic supply. It has been
suggested that a concomitant rise in mitochondrial
reactive oxygen species may prime stem cells for lineage
differentiation [66, 67]. The large number of observa-
tions identifying stem cell properties affected by energy-
responsive molecules and signaling pathways raises
questions about the fate of stem cells under conditions
when metabolic homeostasis is perturbed. The literature
suggests that abnormal endocrine signaling in organisms
in extreme metabolic states has a substantial impact on
proliferation and differentiation of multiple stem cell
populations throughout the body [68]. It is also possible
that variations in metabolism during gestation contrib-
ute to changes in offspring through their effects on stem
cells. For example, low energy levels and the associated
hormonal signals that occur in the pregnant mother
could be directly transmitted to the offspring through
the placenta, resulting in either transient or permanent
changes in embryonic stem cells. Therefore, it seems
that risk factors for schizophrenia such as famine,
hipoxia and low birth weight could be implicated in per-
manent changes to stem cells leading to altered brain
neural-development, as well as some alterations that are
still presented in adulthoods, like disturbed neural plasti-
city and increased ROS production.
Conclusions
In this study, data integration provided by different sam-
ple types (single cell versus tissue bulk) and methodolo-
gies were used to contribute to a better understating the
schizophrenia. This model allowed us to examine the
influence of the neuronal cells to the schizophrenic brain
through the involvement of genes related to neuronal
differentiation and cell metabolism. We identified a non-
conserved module based on a co-expression network in
schizophrenia compared to health controls that enabled
us to predict that metabolic changes involving oxidativestress and negative regulation of cell differentiation may
be occurring during early neurodevelopment and prompt-
ing to the development if schizophrenia. Several genes
from this module were associated to schizophrenia by
other studies and we revealed new candidates (ARMC8,
BCL11A, CDO1 and FOXG1) to be disrupted during neur-
onal differentiation in patients with schizophrenia.
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